BRIEF published on 04/23/2025 at 09:10, 1 year 1 month ago BioNxt Solutions Advances in MS Treatment Study Multiple Sclerosis Cladribine Drug Delivery Innovation BioNxt Solutions Bioequivalence Study
PRESS RELEASE published on 04/23/2025 at 09:05, 1 year 1 month ago BioNxt Solutions Prepares for Human Bioequivalence Study For MS BioNxt Solutions Inc. reports advanced preparation for human bioequivalence study of BNT23001, a novel sublingual thin-film Cladribine formulation for Multiple Sclerosis treatment BioNxt Solutions Inc. Multiple Sclerosis Treatment Sublingual Thin-Film BNT23001 Human Bioequivalence Study
BRIEF published on 03/15/2025 at 00:05, 1 year 3 months ago BioNxt Solutions Closes Final Tranche of Convertible Debenture Offering Private Placement Convertible Debenture Warrants Financing BioNxt Solutions
PRESS RELEASE published on 03/15/2025 at 00:00, 1 year 3 months ago BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement BioNxt Solutions Inc. completes final tranche of convertible debenture Offering for $900,000. Funds to be used for product dev, IP, debt repayment, and working capital Private Placement Convertible Debenture Healthcare BioNxt Solutions Inc. Drug Delivery Technologies
BRIEF published on 03/01/2025 at 01:40, 1 year 3 months ago BioNxt Solutions Secures $1.6 Million in Convertible Debenture Private Placement Private Placement Convertible Debenture Investment BioNxt Solutions Proceeds Utilization
PRESS RELEASE published on 03/01/2025 at 01:35, 1 year 3 months ago BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement BioNxt Solutions Inc. closes first tranche of convertible debenture units Offering, raising $1.6M. Proceeds for product development, IP filings, debt repayment, and working capital Private Placement BioNxt Solutions Inc. Intellectual Property Product Development Convertible Debenture Units
BRIEF published on 02/24/2025 at 15:05, 1 year 3 months ago BioNxt Solutions Launches Debenture Unit Financing Private Placement Regulatory Approvals Convertible Securities Debenture Units Compensation Warrants
PRESS RELEASE published on 02/24/2025 at 15:00, 1 year 3 months ago BioNxt Solutions Announces Debenture Unit Financing BioNxt Solutions Inc. announces a non-brokered private placement of debenture units and Finders Warrants, expecting gross proceeds of up to $2,500,000, subject to regulatory approvals Private Placement BioNxt Solutions Inc. Regulatory Approvals Debenture Units Finders Warrants
BRIEF published on 02/22/2025 at 01:40, 1 year 3 months ago BioNxt Solutions Inc. Clarifies Promotional Activity Agreements Investor Relations German Market BioNxt Solutions Promotional Activities Option Plan
PRESS RELEASE published on 02/22/2025 at 01:35, 1 year 3 months ago Clarification of Promotional Activities BioNxt Solutions Inc. provides a clarification on engaging Apaton Finance GmbH and Cayo Ventures GmbH for investor relations services in Germany and Switzerland Investor Relations Services BioNxt Solutions Inc. Apaton Finance GmbH Cayo Ventures GmbH German Translations
Published on 06/13/2026 at 04:50, 1 day 23 hours ago BTU Additional Details Regarding Recent Acquisition
Published on 06/13/2026 at 02:00, 2 days 2 hours ago Battery X Metals Appoints Automotive Industry Professional from Canadian Subsidiary of One of the World's Leading Premium Automobile Manufacturers, Headquartered in Munich, Germany, to its Advisory Board to Advance Commercialization of Its Patent-Pending
Published on 06/12/2026 at 23:15, 2 days 5 hours ago BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/12/2026 at 22:30, 2 days 6 hours ago Fox River Provides Reminder To Vote And Updated Dissent Rights
Published on 06/12/2026 at 15:14, 2 days 13 hours ago Reeflex Solutions Inc. Reports Voting Results From Annual and Special Meeting of Shareholders
Published on 06/14/2026 at 14:50, 13 hours 45 minutes ago Zug voters say yes to Metalli development plan
Published on 06/14/2026 at 13:30, 15 hours 5 minutes ago Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Published on 06/14/2026 at 10:42, 17 hours 53 minutes ago LightOn Demonstrates the Flexibility of Its OCR Model by Adapting It to Arabic Through Targeted Training.
Published on 06/13/2026 at 08:18, 1 day 20 hours ago EQS-Adhoc: AT&S Austria Technologie & Systemtechnik AG: AT&S expands AI substrate capacity in Kulim and increases outlook for 2026/27
Published on 06/13/2026 at 01:05, 2 days 3 hours ago OpenText to Create 400 Jobs with €105 Million Investment in Cork and Galway to Expand Agentic AI and Sovereign Cloud in Europe
Published on 06/12/2026 at 18:31, 2 days 10 hours ago Share retention commitments (Dutreil agreement)
Published on 06/12/2026 at 09:00, 2 days 19 hours ago Pricing of Green Senior Secured Notes due 2031 by Neoen FINCO PLC
Published on 06/11/2026 at 17:45, 3 days 10 hours ago BAIKOWSKI: Annual General Meeting of June 11, 2026 - Dividend of €0.30 per share, to be paid out on June 30, 2026
